Neumora Therapeutics Inc (NMRA) Sheds More Light on Phase 1b Study of NMRA-511

Neumora Therapeutics Inc (NASDAQ:NMRA) is among the best NASDAQ penny stocks to buy according to analysts. Presenting at the Guggenheim Emerging Outlook: Biotech Summit 2026 on February 11, Neumora executives shared additional data from the Phase 1b study of drug candidate NMRA-511. Neumora is developing NMRA-511 as a treatment for agitation in Alzheimer’s disease patients.

At the summit, Neumora President Josh Pinto reiterated positive results from the study and emphasized what that study was designed to show. Notably, the study was meant to estimate effect size rather than statistical significance.

According to Pinto, the effect sizes were met with a favorable safety and tolerability profile. The executives believe this outcome provides a chance to advance to higher dose testing in 2026.

Neumora Therapeutics Inc (NMRA) Sheds More Light on Phase 1b Study of NMRA-511

In other related news, on January 12, Leerink Partners launched coverage on Neumora Therapeutics (NASDAQ:NMRA) stock with an Outperform rating and a price target of $8. For this action, the firm pointed to Neumora’s diverse portfolio, noting that several programs have “a good chance of success.”

Based in Watertown, Massachusetts, Neumora Therapeutics Inc (NASDAQ:NMRA) is a clinical-stage biopharmaceutical company. It’s focused on developing treatments for brain diseases, neurodegenerative diseases, and neuropsychiatric disorders.

While we acknowledge the potential of NMRA as an investment, our conviction lies in the belief that some AI stocks hold greater promise for delivering higher returns and have limited downside risk. If you are looking for an AI stock that is more promising than NMRA and that has 100x upside potential, check out our report about the cheapest AI stock.

READ NEXT: 40 Most Popular Stocks Among Hedge Funds Heading Into 2026 and 11 Best Italian Stocks to Buy in 2026.

Disclosure: None.  Follow Insider Monkey on Google News.